Operator: Greetings. And welcome to the Tenon Medical Fourth Quarter and Full Year 2024 Financial Results and Corporate ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

SABR is a well-established therapy in both the curative and metastatic setting, however, its ablative potential may not be as high as suggested by ...